Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, is currently being eva... Read more
School District of Philadelphia
5 followers
Vaxcyte
5 followers
DECA
4 followers
Mentor Collective
4 followers
FieldGuide
4 followers
Tango Therapeutics
3 followers
James Madison University
2 followers
Mississippi State University
2 followers
Capricor Therapeutics
2 followers
Ascidian Therapeutics
2 followers
23andMe Research Institute
91 followers
Tempus Labs
33 followers